Patent application number | Description | Published |
20110318366 | BIOLOGIC COMPOUNDS - The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders. | 12-29-2011 |
20120023600 | COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition. | 01-26-2012 |
20130058934 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES - The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof. | 03-07-2013 |
20130064823 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES - The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof. | 03-14-2013 |
20130251703 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN III AND DOMAIN IV OF HER3 - The present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the HER3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. The invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of HER3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof. | 09-26-2013 |
20130273029 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN II OF HER3 - The present invention relates to antibodies or fragments thereof that target an epitope of a HER3 receptor residing in domain 2 of the HER3 receptor to block both ligand-dependent and ligand-independent signal transduction and tumor growth; and compositions and methods of use thereof. | 10-17-2013 |
20130330324 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) - This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast). | 12-12-2013 |
20140170147 | COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition. | 06-19-2014 |
20140341901 | COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition. | 11-20-2014 |